MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

CSF1R-IN-2

CAS No. : 2271119-26-5

MCE 站：CSF1R-IN-2

产品活性：CSF1R-IN-2 (compound 5) 是 SRC，MET 和c-FMS 的口服有效抑制剂, 其对SRC，MET 和c-FMS 的 IC₅₀ 值分别为 0.12 nM，0.14 nM 和 0.76 nM。

研究领域：Protein Tyrosine Kinase/RTK

作用靶点：Src  |  c-Met/HGFR  |  c-Fms

In Vitro: CSF1R-IN-2 (compound 5) causes the suppression of MET autophosphorylation as well as the downstream STAT3, ERK and AKT phosphorylation at IC₅₀ values of around 1-3 nM in SNU-5 and MKN-45 cell lines.

In Vivo: CSF1R-IN-2 (compound 5: p.o., BID, 13 days) treatment results in an 85% tumor regression and no body weight loss is observed after 21 days treatment in mice.
CSF1R-IN-2 (compound 5: p.o., BID, 10 days) demonstrates the ability to inhibit tumor growth at 44% and 67% at the dose of 5 mg/kg, BID and 15 mg/kg, BID, respectively in SCID/Beige mice.
CSF1R-IN-2 (compound 5) inhibits MET activity in MKN-45 tumors following oral administration in mice.

相关产品：Bioactive Compound Library Plus  |  Kinase Inhibitor Library  |  Protein Tyrosine Kinase Compound Library  |  Anti-Cancer Compound Library  |  Reprogramming Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Bosutinib  |  PP2  |  GW2580  |  SU6656  |  Src Inhibitor 1  |  PHA-665752  |  WH-4-023  |  2-Phospho-L-ascorbic acid trisodium  |  Pelitinib  |  Scutellarein  |  PP1  |  1-Naphthyl PP1  |  1-NM-PP1  |  Lck Inhibitor  |  RK-24466  |  SU11274  |  SRI 31215 TFA  |  Ki20227  |  Tolimidone  |  A-770041  |  PP121  |  PP58  |  PD173955  |  MNS  |  AZD7507  |  c-Met inhibitor 1  |  AZM475271  |  PLX647  |  7-Hydroxy-4H-chromen-4-one

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。